title: Modulation of 3,4-methylenedioxymethamphetamine effects by endocannabinoid system.
abstract: The amphetamine derivative 3, 4 Methylenedioxymethanphetamine (MDMA) is a powerful central nervous system stimulant that displays numerous pharmacological effects, including neurotoxicity. MDMA, or ecstasy, acts by inducing the release of different neurotransmitters depending on the animal species and, in particular, it produces the release of serotonin and dopamine. MDMA induces rewarding and reinforcing effects in rodents, primates and humans, and is currently consumed as an illicit psychostimulant among young people. One of the most reported side effects is the hyperthermic effect and the neurotoxicity on central serotonergic and dopaminergic neurons, depending on the species of animal. It seems that MDMA may also produce neurotoxic effects in humans. To date, the most consistent findings associated to MDMA consumption in humans relate to cognitive deficits in heavy users. MDMA when consumed as an illicit psychostimulant is commonly co-used with other abusers, being frequently associated with cannabinoids. The interaction between MDMA and cannabis effects is complex. Cannabis derivatives act on endocannabinoid system. Thus, at cellular levels, cannabinoids acting through CB1 cannabinoid receptors display opposite effects to those induced by MDMA, and they have been reported to develop neuroprotective actions, including the blockage of MDMA induced neurotoxicity, in laboratory animals. However, cannabis use is a recognized risk factor in the presentation and development of neuropsychiatric disorders, and also contributes to the development of psychological problems and cognitive failures observed in MDMA users. This paper represents a brief overview of the pharmacological interaction between MDMA and cannabis derivatives acting in the endocannabinoid system. We have evaluated recent findings in the literature of the most representative pharmacological effects displayed by both types of drugs. We analyze both, the synergic and opposite effects produced by these two compounds and we have found a gap regarding the negative consequences of long-term human consumption of MDMA alone or in combination with cannabis.
authors.affiliation: Neurobiology of Behavior Research Group (GReNeC)., Department of Health and Experimental Sciences., University Pompeu Fabra., IMIM (Hospital del Mar Research Institute), Barcelona Biomedical Research Park (PRBB)., C/ Dr. Aiguader, 08003 Barcelona, Spain. olga.valverde@upf.edu.
authors.forename: Olga
authors.initials: O
authors.lastname: Valverde
authors.forename: Marta
authors.initials: M
authors.lastname: Rodríguez-Árias
mesh_terms: D019969:Amphetamine-Related Disorders / Q000503:physiopathology; D000818:Animals; D002186:Cannabinoids / Q000009:adverse effects / Q000494:pharmacology*; D002188:Cannabis / Q000737:chemistry; D003072:Cognition Disorders / Q000139:chemically induced; D063388:Endocannabinoids / Q000378:metabolism*; D006801:Humans; D002189:Marijuana Abuse / Q000503:physiopathology; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D012054:Reinforcement, Psychology; D012201:Reward; D013997:Time Factors
chemical_list: D002186:Cannabinoids; D063388:Endocannabinoids; D018817:N-Methyl-3,4-methylenedioxyamphetamine